Sources said Thermo Fisher Scientific and Celltrion are among those competing to acquire the biopharma solutions business of medical device maker Baxter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. (Reuters)
A deadly fungus that is considered an urgent public health threat by the Centers for Disease Control and Prevention spread at an “alarming rate” during the pandemic, the agency said this week. Candida auris, a drug-resistant fungus that health officials hoped to contain is now in more than half the 50 states, according to a new research paper. (The New York Times)
Artificial intelligence has developed a treatment for cancer in just 30 days and can predict a patient’s survival rate. In a new study published in the journal Chemical Science, researchers at the University of Toronto along with Insilico Medicine developed a potential treatment for hepatocellular carcinoma with an AI drug discovery platform called Pharma.AI. (New York Post)
Foxo Therapeutics, a Minneapolis biotechnology company, is under investigation by the Securities and Exchange Commission. The move came just two months after Foxo went public through a merger with a special purpose acquisition company. Foxo was the only newly public company in Minnesota in 2022. (The Star Tribune)
President Joe Biden signed legislation to declassify information on the origin of the COVID-19 pandemic. The House had passed the bill earlier this month, but the White House had been non-committal about whether Biden would sign it into law. (The Hill)
